FindTrial
Sign In

Buprenorfina TDS in old patients with chronic pain not give moderated cancer of intensita serious. Study in open, of Phase IV, not controlled, multicentric, spontaneous - Buprenorfina TDS in old patients with chronic pain does not give moderated cancer of intensita from

Buprenorfina TDS in old patients with chronic pain not give moderated cancer of intensita serious. Study in open, of Phase IV, not controlled, multicentric, spontaneous - Buprenorfina TDS in old patients with chronic pain does not give moderated cancer of intensita from

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-000483-25-IT
Enrollment
160
Registered
2007-04-03
Start date
2007-01-15
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

old patients ultra 65 with chronic pain do not give cancer MedDRA version: 6.1 Level: PT Classification code 10028411

Interventions

Trade Name: TRANSTEC Pharmaceutical Form: Transdermal patch Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 70- Trade Name: TRANSTEC 3CER 20MG 35MCG/H Pharmaceutic

Sponsors

OSPEDALE ISRAELITICO DI ROMA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Pazienti of both seies, eta equal or advanced to 65 years. Pazienti in regimen of ordinary stay in hospital, DH or ambulatoriali. Pazienti with chronic pain do not give present cancer from at least 3 months and of intensita from moderated serious to VAS base them. to 5 cm . Pazienti collaborating in a position to supplying the informed consent written. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patologie neurological delirium tremens, endocranica hypertension, diseases convulsive and neuromuscular myasthenia gravis . cardiorespiratory, coagulopatiche, metabolic, hepatic, renal, gastrointestinal, serious and/or scompensate. Patologie neoplastiche Patologie in action. extend, such cutaneous. Alterazioni to prevent the correct application of the doily. Anamnesi positive for alcoholism, abuse of drugs or drug use. Psicosi in acute phase. Corrected inferior MMSE to 14 for eta and scolarita . Pazient of age inferior to the 65 years. Pazienti with ipersensibilita famous to the oppioidi. intolleranti. Pazienti on anamnestica base to the doilies. Pazienti in therapy with IMAO. Pazienti subordinates to acupuncture.

Design outcomes

Primary

MeasureTime frame
Main Objective: To estimate analgesic effectiveness and tollerabilita of Buprenorfina TDS in old patients with particular attention to the cognitivo/comportamentale state.;Secondary Objective: To estimate analgesic effectiveness and tollerabilita of Buprenorfina TDS in old patients with particular attention to the cognitivo/comportamentale state.;Primary end point(s): Intensita of the pain measured by means of Visual Analogic Scale VAS or Be cognitive, disturbs of the behavior, depression, capacita it works them and self-sufficiency by means of the following scales of appraisal index of Barthel, CIRS, MMSE, HDRS-17 items, NPI, SF12.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026